Elevated sPD-L1 also associated with the presence of muscle invasive disease and metastasis in patients with bladder cancer [21], lymph node metastasis in patients with colorectal cancer [54], higher Gleason scores in prostate cancer [59], less differentiated tumors and increased invasion and metastasis in renal cell carcinoma patients [58], and a greater residual tumor burden in patients with ovarian cancer [60]. This evidence concerns the gene SPDL1 and ovarian carcinoma.